Drug Discovery & Molecular Design software & AI news

Showing 375 results

Oct 21, 2026

Insilico Medicine and Servier Achieve First Milestone in AI-Driven R&D Collaboration, Triggering An undisclosed Milestone Payment

Two programs under the multi-year R&D collaboration have initiated and completed target nomination since its early 2026 announcement.Insilico reached the first R&D milestone using its proprietary Pharma.AI platform, triggering an undisclosed milestone payment from Servier.The multi-targets oncology collaboration of both parties, announced in early 2026, carries a total value of up to $888 million with $32 million in upfront and near-term R&D payments.CAMBRIDGE, Mass., Oct. 20, 2026 /

Oct 19, 2026

ACRO Innovation Day x AI Brings Industry Leaders Together to Advance AI-Driven Drug Discovery

SAN FRANCISCO, Oct. 19, 2026 /PRNewswire/ -- On October 13, 2026, ACROBiosystems hosted ACRO Innovation Day x AI at The Hangar in South San Francisco, California, bringing together biotech founders, industry leaders and scientists to explore how experimental validation can advance AI-driven drug discovery and biologics development. Following opening remarks by Mike Chen, Founder, Chairman and CEO of ACROBiosystems, three presentations from ACROBiosystems and two panel discussions examined how to

Oct 19, 2026

Korea University Study Uses Artificial Intelligence to Design Potential Antiviral Compounds

New study combines AI-guided molecular design with experimental validation to identify potential inhibitors of a host enzyme involved in viral replicationSEOUL, South Korea, Oct. 19, 2026 /PRNewswire/ -- Viral infections can be difficult to treat as viruses evolve rapidly, allowing them to develop resistance to drugs designed to attack viral proteins directly. One alternative is host-directed therapy (HDT), an emerging medical approach that treats infections by targeting the host's own biologica

A minimalist representation of a lipid nanoparticle in a dark color scheme.

Oct 19, 2026

Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery

Eli Lilly has entered a strategic partnership with Hong Kong-based Metis TechBio, valued at up to $1.1 billion, to enhance its AI-driven drug delivery capabilities through lipid nanoparticles.This collaboration will leverage Metis' innovative platform, AiLNP, which is touted as the first algorithm for generating ionizable lipids. This technology utilizes a comprehensive lipid library and advanced screening methods to identify lipid nanoparticles that can effectively target tissues, thereby exped

Oct 19, 2026

10,000 Protein Designs, One Wet Lab: Poreva Open Launches First Challenges

Five protein design challenges. Standardized wet-lab validation. Open experimental data. Registration opens October 19.SUZHOU, China, Oct. 19, 2026 /PRNewswire/ -- A promising protein design is only the beginning. The real test comes in the lab.MegaRobo Technologies, a technology company building "Intelligence Infrastructure for the Physical World", launched Poreva Open, a new global AI protein design competition challenging teams worldwide to put AI-generated designs to the test. More than 10,0

Flat illustration of a drug compound and a symbol for cardiometabolic disease

Oct 16, 2026

AI in drug discovery & development: News watch, October 2026

Recent advancements in the biopharma sector highlight significant partnerships and funding initiatives aimed at leveraging AI for drug discovery and development, underscoring the industry's growing reliance on technology to address complex health challenges.AstraZeneca has formed a substantial partnership with insitro, committing $40 million upfront and potentially up to $1.5 billion in total, to utilize insitro's AI-driven platform for researching drug targets related to cardiometabolic disease

Oct 15, 2026

XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation

Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage reference molecules targeting the same target.In non-human primates, a single dose maintained robust target-protein suppression for months, demonstrating a durable pharmacodynamic effect and supporting the potential for extended dosing intervals.Using Kodexia™ platform, XtalPi applied generative AI to identify a previously unexplored active targe

Oct 15, 2026

Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments

PALO ALTO, Calif.--(BUSINESS WIRE)--Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease with few effective treatments.The collaboration plans to combine Mayo Clinic’s clinical and neuropathology expertise with Transcripta Bio’s transcriptomic drug-discovery platform to build a hig

Oct 15, 2026

insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Collaboration applies insitro's Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical needinsitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and commercial milestones, and tiered royaltiesSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, an AI company unlocking causal human biology to systematically generate high-value therapeutics to treat grievous illness, today anno

Oct 15, 2026

DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery

Funding from the Gates Foundation supports development of open-access AI models, workflows and datasets to help researchers identify new tuberculosis (TB) targets for faster and more cost-effective drug discoveryProject will analyse hundreds of essential TB proteins at proteome scale, demonstrating Dalton’s ability to tackle complex scientific challenges Collaboration with Ersilia will make findings accessible to researchers across the Global South LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Da

Oct 14, 2026

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise- This is the Company’s second collaboration building on the universal PRO-XTEN® masking technologySAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-X

Oct 14, 2026

Rakovina Therapeutics Secures Exclusivity on Optimized kt-5000 Lead Profile from Variational AI

Agreement provides Rakovina exclusive access to its optimized kt-5000 target profile and extends AI-powered lead optimization through year-end at no additional costVANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced an amendment (the “Amendment”) and extension to its research services agreement with

Back to start
Previous
Page 4 of 32
Next

Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Platform

Domains

Services

Legal